At a glance
ClinicalIndex Comparison RecordN/ACompleted· 15 enrolled
Drug / intervention
Ketone Monoesterdietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ketone Monoester Supplementation in Cystic Fibrosis: A Pilot and Feasibility Study
In Brief
A clinical study evaluating Ketone Monoester for Cystic Fibrosis. Completed, enrolled 15 participants across 1 site.
Detailed Summary
This study will examine the effects of a novel ketone monester supplement on patients with cystic fibrosis experiencing an acute pulmonary exacerbation requiring hospitalization. Patients will undergo standard testing along with blood sampling to examine concentrations of inflammatory markers. Patients will then receive the ketone supplement for 5 days followed by post-testing to examine changes in pulmonary function and inflammatory markers
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesUnited States
Timeline
N/ACompletedFinished
20222023202420252026
First PostedJun 2021
Enrollment StartNov 2021
Primary CompletionApr 2023
TodayJul 2026
First PostedJun 24, 2021
Enrollment StartNov 1, 2021
Primary CompletionApr 30, 2023
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 5.0 years ago
Interventions
Ketone Monoesterdietary
Ketone supplement will be taken by mouth at a dose of 15 mL twice per day